ライフサイエンスコーパス: MSC

1 MSC therapy reduced crypt dropout in the small intestine

2 MSCs and CIMVs-MSCs reduced serum levels of anti-sheep r

3 MSCs are naturally pro-angiogenic and proreparative, and

4 MSCs are very susceptible to in vitro culture environmen

5 MSCs can, however, either promote or suppress tumor grow

6 MSCs derived from PDL and gingiva demonstrated multipote

7 MSCs exposed to Ag(+) prior to/during osteogenic differe

8 MSCs have inherent immunomodulatory characteristics, tro

9 MSCs isolated from bone marrow of wild type and Sdc3(-/-

10 MSCs showed a stable and predictable metabolite and secr

11 MSCs were seeded on the extraluminal side of hollow fibe

12 To achieve this goal, 3D MSC sheets are prepared, exploiting spontaneous post-det

13 Results support 3D MSC sheets' chondrogenic differentiation to hyaline cart

14 e prediction on the therapeutic outcome of a MSC therapy based on the patient's conditions would prov

15 entiation checkpoint mechanism for activated MSCs and has clinical relevance for the activity of PRL3

16 pended domains, characteristic of nearly all MSC constituents.

17 artial or complete crystal structures of all MSC constituents have been reported; however, the struct

18 xide, inter-protein cross-links spanning all MSC constituents were observed, including cross-links be

19 for the safety and efficacy of an allogenic MSC-based intramammary therapy for the treatment of bovi

20 ated the safety and efficacy of an allogenic MSC-based intramammary therapy in dairy cows with experi

21 nal effect in CKD mice) into mice, alongside MSCs and ECFCs.

22 MSCs for sixty passages significantly alters MSC proliferation, differentiation and structure.

23 tion of a subset of contractile SMCs into an MSC-like intermediate state that generated osteoblasts,

24 blocked interaction between tumor cells and MSCs injected into the contralateral gland, as evidenced

25 nd, evidenced by the lack of tumor growth at MSC-injected site.

26 s 4 and 5) or a suspension of 2.5 x 10(7) AT-MSCs (MSC; days 4 and 5).

27 f repeated doses of 2.5 x 10(7) allogenic AT-MSCs did not induce clinical or immunological response i

28 ministration of two doses of bovine fetal AT-MSCs in healthy cows did not induce changes in clinical

29 a 2.5 x 10(7)-suspension of bovine fetal AT-MSCs on experimental days 1 and 10.

30 cally increasing mitochondria transfer to BM MSC.

31 ppaB signaling pathway in bone marrow and BM-MSC of DeltaNC16A mice.

32 ed by bone marrow mesenchymal stem cells (BM-MSC), and its functional deficiency leads to myeloid hyp

33 ne marrow-derived mesenchymal stem cells (BM-MSC), and Michigan Cancer Foundation-7 (MCF-7) breast ca

34 uces the release of G-CSF from DeltaNC16A BM-MSC in vitro and the level of serum G-CSF in DeltaNC16A

35 regulating NF-kappaB signaling pathway in BM-MSC.

36 ures can facilitate the mineralization of BM-MSC cells, demonstrated by the formation of clusters aro

37 effect of the drugs on mineralization of BM-MSCs are investigated using a variety of characterizatio

38 ers showcased their great potential to boost MSCs population required for stem cell therapy of bone d

39 significantly different between CBT and both MSCs (P < 0.05) and indicated greater instability of the

40 ak values being higher for CBT than for both MSCs.

41 che cells were not significantly improved by MSC therapy.

42 mononuclear cells (PBMCs) were suppressed by MSC bioreactor culture confirmed by a durable change in

43 promotive/suppressive mechanisms induced by MSCs loaded with oncolytic viruses.

44 , the effects of normal and diseased cardiac MSCs on myocyte electrophysiology remain unclear.

45 -mercarpotopropionic acid as the ligand, CdS MSC-360 develops in a mixture of a primary amine and wat

46 m-temperature aqueous-phase formation of CdS MSCs.

47 The resulting CdS MSCs display a sharp optical absorption peak at about 36

48 eous-phase, room-temperature approach to CdS MSCs, together with an exploration of their evolution pa

49 S1) as a regulator of mesenchymal stem cell (MSC) chondrogenesis.

50 tion (LIV), increases mesenchymal stem cell (MSC) osteogenesis and proliferation.

51 The mesenchymal stem cell (MSC), known to remodel in disease and have an extensive

52 Mesenchymal stem cell (MSC)-based therapy has shown great promises in various a

53 reprogramming into a mesenchymal stem cell (MSC)-like state.

54 Rationale: Mesenchymal stromal cell (MSC) therapy is a promising intervention for acute respi

55 ibacterial effects of mesenchymal stem cell (MSCs), we evaluated the safety and efficacy of an alloge

56 y acid (FA) analysis and milk somatic cells (MSC) were obtained from all cows at the beginning of the

57 tal trauma, in which mesenchymal stem cells (MSC) differentiate into osteochondrogenic cells instead

58 We report that BM mesenchymal stromal cells (MSC) undergo massive damage to their mitochondrial funct

59 ndantly available mesenchymal stromal cells (MSC) were reprogrammed into induced endothelial cells (i

60 sis of cocultures of mesenchymal stem cells (MSCs) and articular chondrocytes (ACs) in PLL-loaded hyd

61 Melanoma stem cells (MSCs) are characterized by their unique cell surface pro

62 Multipotent mesenchymal stem cells (MSCs) are important sources for cartilage regeneration.

63 Mesenchymal stem cells (MSCs) are used extensively in developing tissue engineer

64 ncreasingly focus on mesenchymal stem cells (MSCs) as allogeneic cell sources, based on availability

65 ng chondrogenesis of mesenchymal stem cells (MSCs) by Infinium 450 K methylation array.

66 Mesenchymal stem cells (MSCs) derived from periodontal ligament (PDL) and gingiv

67 bone marrow mesenchymal stromal/stem cells (MSCs) during aging.

68 viscosity changes in mesenchymal stem cells (MSCs) during osteogenic and chondrogenic differentiation

69 bone marrow derived mesenchymal stem cells (MSCs) has been widely studied and the recent observation

70 epressant effects of mesenchymal stem cells (MSCs) have been reported, the potential benefit of this

71 rapeutic efficacy of mesenchymal stem cells (MSCs) in regenerative medicine has been documented in ma

72 d communication with mesenchymal stem cells (MSCs) injected into contralateral mammary gland, evidenc

73 erentiation of human mesenchymal stem cells (MSCs) into osteoblasts.

74 ation of bone marrow mesenchymal stem cells (MSCs) into the fusion materials.

75 Mesenchymal stem cells (MSCs) loaded with oncolytic viruses are presently being

76 factors secreted by mesenchymal stem cells (MSCs) promote angiogenesis in vivo.

77 esicles derived from mesenchymal stem cells (MSCs) represent a novel approach for regenerative and im

78 ers were seeded with mesenchymal stem cells (MSCs) using a dynamic culture technique for cells expans

79 telets, neutrophils, mesenchymal stem cells (MSCs), and bacteria have been utilized to advance drug d

80 Mesenchymal stem cells (MSCs), are excellent candidates for engineering bone, bu

81 Herein, mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs) and c-Kit(+)

82 ed throughout life by melanocyte stem cells (MSCs), play a critical role in pigmentation and melanoma

83 eoblastogenesis from mesenchymal stem cells (MSCs), which can also differentiate into adipocytes.

84 l signals applied to mesenchymal stem cells (MSCs).

85 breast tumor cells + mesenchymal stem cells (MSCs)/human lung fibroblasts (HLFs)/HUVECs) and the extr

86 ion of endogenous mesenchymal stromal cells (MSCs) are critical for bone regeneration.

87 Mesenchymal stem/stromal cells (MSCs) are multipotent cells that are emerging as the mos

88 Multipotent Mesenchymal Stem/Stromal Cells (MSCs) are widely used in cellular therapy for joint repa

89 of donor-derived mesenchymal stromal cells (MSCs) has been investigated in diverse diseases(1), incl

90 chymal stem cells/multipotent stromal cells (MSCs) has been proposed to augment the reparative capaci

91 al application of mesenchymal stromal cells (MSCs) has generated growing enthusiasm as an innovative

92 Bone marrow mesenchymal stromal cells (MSCs) have been studied for decades as potent immunomodu

93 infuse allogeneic mesenchymal stromal cells (MSCs) to provide a more generalized treatment for RDEB.

94 have transplanted mesenchymal stromal cells (MSCs) without co-administration of a hematopoietic graft

95 show that Gli1(+) mesenchymal stromal cells (MSCs), previously shown to contribute to myofibroblasts

96 human bone marrow mesenchymal stromal cells (MSCs).

97 s, primarily mesenchymal stem/stromal cells (MSCs).

98 normal HSPCs, and mesenchymal stromal cells (MSCs).

99 ming cells (human mesenchymal stromal cells [MSCs] and endothelial colony-forming cells [ECFCs]) may

100 Mechanically separated chicken (MSC) was obtained by two different separation methods (M

101 Also, CIMVs-MSCs contained a cytokine repertoire reflective of the p

102 MSCs and CIMVs-MSCs reduced serum levels of anti-sheep red blood cell a

103 ted with natural EVs, whereas MSCs and CIMVs-MSCs suppressed antibody production in vivo.

104 CIMVs were generated from murine MSC (CIMVs-MSCs) and their cytokine content and surface marker expr

105 ve investigated the biodistribution of CIMVs-MSCs in vivo and demonstrated that CIMVs-MSCs localized

106 ed the immune-modulating properties of CIMVs-MSCs in vivo using standard preclinical tests.

107 MVs-MSCs in vivo and demonstrated that CIMVs-MSCs localized in liver, lung, brain, heart, spleen and

108 For the first time, we show that CIMVs-MSCs retain parental MSCs phenotype (Sca-1(+), CD49e(+),

109 6-InP MSCs could be converted to F360-InP:Cl MSCs, then to F399-InP:Cl MSCs.

110 ted to F360-InP:Cl MSCs, then to F399-InP:Cl MSCs.

111 ), suggesting that a subpopulation of clonal MSCs was sensitive to Ag(+) exposure.

112 es to semiconductor CdS magic-size clusters (MSCs) and the formation pathway have remained relatively

113 Magic-sized clusters (MSCs) can be isolated as intermediates in quantum dot (Q

114 nd generation time, multispecies coalescent (MSC) methods can potentially overcome these challenges.

115 d on the well-known multispecies coalescent (MSC) model.

116 er, this study demonstrates that coculturing MSCs with ACs can greatly enhance the chondrogenicity of

117 de in a large multi-tRNA synthetase complex (MSC).

118 ransdifferentiation of Wharton jelly-derived MSC (WJ-MSC) into iEC.

119 the efficacy of a human bone marrow-derived MSC therapy delivered at 3 h or 30 h in ameliorating rad

120 The therapeutic application of iPSC-derived MSCs may now be explored in diverse inflammatory and imm

121 CYP-001 (iPSC-derived MSCs) is produced using an optimized, good manufacturing

122 and show that pancytopenia persists despite MSC therapy.

123 expansion phase by replating the dissociated MSC aggregates onto planar tissue culture surfaces.

124 imate-specific lncRNA, is upregulated during MSC chondrogenesis and appears to act directly downstrea

125 is using L-buthionine sulfoxamine eliminated MSC clonogenicity in the presence of Ag(+), which was re

126 The implantation of encapsulated MSCs (eMSCs) into the lateral ventricle counteracted dep

127 nomodulatory aspects of naive and engineered MSCs, and discuss strategies for increasing the potentia

128 Initially, engineered MSCs incorporated ex vivo into RDEB grafts, their presen

129 contrast, intravenously injected engineered MSCs were undetectable within grafts and lacked anchorin

130 orrection may be achievable using engineered MSCs, strategies for systemic administration require fur

131 strategies that have emerged in engineering MSC behavior for bone and cartilage tissue engineering,

132 leterious, pro-fibrotic effects of exogenous MSCs once intravitreally injected into clinical patients

133 cyclical aggregation as a means of expanding MSCs to maintain stem cell functionality.

134 Both types of stem cells expressed MSC precursor markers, including CD73, CD90, and CD105,

135 locollagen provides a suitable substrate for MSC attachment and enhancing chondrogenic differentiatio

136 which was below toxic levels determined for MSCs in vitro (EC(50), 33 uM).

137 a molecular level, surviving colony-forming MSCs treated with Ag(+) demonstrated a significant upreg

138 free, hyaline-like cartilage constructs from MSCs for future transplantable articular cartilage regen

139 Vessels derived from MSCs and ECFCs augmented in vivo tubulogenesis by the re

140 lanoblast expansion and differentiation from MSCs.

141 consequently reduced osteoblastogenesis from MSCs, thus suppressing bone formation in vitro and in vi

142 of autophagy eliminated M. tuberculosis from MSCs, and consequently, the addition of rapamycin to an

143 During fibrotic repair, Gli1(+) MSCs integrate hedgehog activation signalling to upregul

144 These findings show that Gli1(+) MSCs integrate hedgehog signalling as a rheostat to cont

145 mpact, 3D structural model of the human holo-MSC.

146 reported; however, the structure of the holo-MSC has not been resolved.

147 To address the critical question of how MSCs loaded with oncolytic viruses affect virotherapy ou

148 However, MSCs face a variety of challenges within the wound micro

149 the inflammatory secretome of cardiac human MSCs (hMSCs) remodels and can regulate arrhythmia substr

150 induced pluripotent stem cell-derived human MSCs (hMSCs) (n = 7) or cell-free carrier vehicle (vehic

151 ic potential of adipose tissue derived human MSCs (hMSCs) mixed with atelocollagen gel.

152 We investigated whether healthy human MSCs could be engineered to overexpress C7 and correct R

153 Moreover, human MSCs were not detected in the bone marrow.

154 biochemical effects of preconditioning human MSCs (hMSCs) for 96 h on a three-dimensional (3D) ECM-ba

155 ber bioreactor to effectively maintain ideal MSC function as a single population while also being abl

156 m was useful to study a model of immobilized MSCs and circulating immune cells and showed that monocy

157 teins and hypoxia can be utilized to improve MSC retention and therapeutic outcome.

158 CACA, PPARGC1, LPIN1 and FABP3 on day 63, in MSC.

159 een surgery and post-operative CT imaging in MSC Marc.

160 stigate more critical properties involved in MSC-induced cartilage repair, and adapted for other clin

161 hosphatase of regenerating liver 3 (PRL3) in MSC regeneration.

162 se that SDC3 might play an important role in MSC biology.

163 wed that monocytes play an important role in MSC driven immunomodulation.

164 resides in early-phagosomal compartments, in MSCs the majority of bacilli were found in the cytosol,

165 ished that M. tuberculosis gains dormancy in MSCs, which serve as a long-term natural reservoir of do

166 eta1, a factor that promotes osteogenesis in MSCs and therefore functioned as an osteoblast-specific

167 ormant M. tuberculosis induced quiescence in MSCs and promoted their long-term survival.

168 ver, apoptotic and metabolically inactivated MSCs have more recently been shown to possess immunomodu

169 386-InP MSCs could be converted to F360-InP:Cl MSCs, then to F39

170 ilies of heterogeneous-atom-incorporated InP MSCs that have chlorine or zinc atoms.

171 orption peak at about 360 nm and are labeled MSC-360.

172 This method was used to track SPIO labelled MSC injected into joints containing osteochondral defect

173 to grafted RDEB skin, resulting in localized MSC persistence with deposition of de novo C7 at the sit

174 The FOXF1 silencing-induced increase in LR-MSC migration was abrogated by genetic and pharmacologic

175 d demonstrate that loss of FOXF1 promotes LR-MSC migration via the ATX/LPA/LPA1 signaling axis.

176 lung-resident mesenchymal stromal cells (LR-MSCs) remain to be elucidated.

177 Fibrotic human LR-MSCs demonstrated lower expression of FOXF1 mRNA and pro

178 RNAi-mediated FOXF1 silencing in LR-MSCs was associated with upregulation of key genes regul

179 a restraint on the migratory function of LR-MSCs via its role as a novel transcriptional repressor o

180 igration were confirmed in FOXF1-silenced LR-MSCs by Boyden chamber.

181 FOXF1-silenced LR-MSCs demonstrated increased ATX activity, while mFoxf1 o

182 Many MSCs exhibit chondrogenic potential as three-dimensional

183 ce-associated (SA) phenotypes of bone marrow MSCs derived from aged mice, as well as promoting their

184 A dosage of 17 - 25 million MSCs was found to achieve optimal cartilage repair.

185 ess and cellular densities may also modulate MSC-derived chondrocyte hypertrophy in vitro.

186 Moreover, MSC-intramammary treatment reduced bacterial count in mi

187 d 5) or a suspension of 2.5 x 10(7) AT-MSCs (MSC; days 4 and 5).

188 this issue, CIMVs were generated from murine MSC (CIMVs-MSCs) and their cytokine content and surface

189 We investigated myeloma-MSC interactions and the effects of such interactions on

190 formation is a direct consequence of myeloma-MSC contact that promotes the differentiation of MSCs in

191 Next, MSCs cotransduced to express C7 and luciferase were deli

192 ytes (OAC) and mesenchymal stromal cells (OA-MSC).

193 nhibiting TGF-betaR1 suppressed MMP-13 in OA-MSC but stimulated it in OAC.

194 ypertrophy, mineralization, and MMP-13 in OA-MSC.

195 tivated BMP signaling-associated SMAD1 in OA-MSC.

196 nd that TGF-beta had different effects on OA-MSC and OAC, and revealed its lateral signaling mechanis

197 RNAseq analysis indicated that OA-MSC expressed the same level of Bone Morphogenetic Prote

198 sus monkeys, that systemic administration of MSC-EVs enhances recovery of function after injury of th

199 olycationic factors on the chondrogenesis of MSC and AC cocultures.

200 ves: To determine the safety and efficacy of MSC therapy in a model of ARDS and ECMO.Methods: ARDS wa

201 significantly compromise on the efficacy of MSC therapy.

202 ntly contribute to the success or failure of MSC-based virotherapy as well as generate new hypotheses

203 extended in vitro expansion induces loss of MSC functionality and its clinical relevance.

204 Current methods of MSC tracking include labelling the cells with Super Para

205 envision the challenges and perspectives of MSC-based cell therapy in SOT.

206 However, quarters of MSC cows had lower CFU log/mL in milk compared to quarte

207 Quarters of MSC group of cows had similar SCC log/mL in milk compare

208 However, the use of MSC therapies is complicated by a lack of understanding

209 ALP activity and calcium content analysis of MSCs-laden microcarriers loaded into injectable hydrogel

210 This is due to both the availability of MSCs at the time of administration and lack of viable ex

211 onal density, the colony-forming capacity of MSCs was significantly reduced in the presence of 10 uM

212 However, delivery of MSCs in the absence of a cytoprotective environment offe

213 contact that promotes the differentiation of MSCs into adipocytes at the expense of osteoblasts.

214 such interactions on the differentiation of MSCs into adipocytes or osteoblasts using single-cell RN

215 ly, mice that received a therapeutic dose of MSCs were significantly less likely to die but experienc

216 We compared the immunomodulatory effect of MSCs, CIMVs and EVs.

217 nfirmed that the immunomodulatory effects of MSCs are mainly communicated via MSC-secreted cytokines;

218 ation enhanced the antidepressant effects of MSCs by attenuating depressive-like behavior of Wistar K

219 ts and mechanisms mediating encapsulation of MSCs remain unexplored.

220 hallenge (+LIV) during in vitro expansion of MSCs for sixty passages significantly alters MSC prolife

221 e effect of LIV during in vitro expansion of MSCs.

222 the hippocampus, whereas the implantation of MSCs without encapsulation or the implantation of eMSCs

223 tro coculture, and subcutaneous injection of MSCs and myeloma cells into mice.

224 he temperature sensing and mechanosensing of MSCs are interconnected via intracellular Ca(2+) Up-regu

225 in vitro data using xenograft mouse model of MSCs confirmed the clinical relevance of CD133 signal as

226 (2) is present, and the formation pathway of MSCs is similar to that in organic-phase approaches.

227 enhanced the attachment and proliferation of MSCs.

228 he present review, the general properties of MSCs are summarized, with a particular emphasis on MSC-m

229 omodulatory, and tissue-repair properties of MSCs.

230 logical analysis indicated that the ratio of MSCs to ACs was an accurate predictor of the degree of l

231 Alternatively, each series of MSCs could be prepared by sequential conversions.

232 his article, we performed a meta-analysis on MSC therapies for cartilage repair using machine learnin

233 sed to test relevant Ag(+) concentrations on MSC function in vitro.

234 re summarized, with a particular emphasis on MSC-mediated impact on the immune system and in the isch

235 evidenced by the lack of tumor formation on MSCs injected site.

236 vascular cell adhesion molecule-1 (VCAM1) on MSCs, leading to the activation of protein kinase C beta

237 ng of tRNA anti-codon binding domains on one MSC face.

238 Herein, we describe a highly osteogenic MSC line generated from induced pluripotent stem cells t

239 ime, we show that CIMVs-MSCs retain parental MSCs phenotype (Sca-1(+), CD49e(+), CD44(+), CD45(-)).

240 tokine repertoire reflective of the parental MSCs, including IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6,

241 Mass spectroscopy of late passage MSC indicated a synergistic decrease of actin and microt

242 r modulating monocyte/macrophage phenotypes, MSC differentiation and HO formation during wound healin

243 ng of patient-specific cartilage repair post MSC therapy.

244 Primary MSCs were subjected to either a control or to a twice-da

245 er-intuitive fact that using tumor-promoting MSCs as carriers is not only helpful but necessary in ac

246 improving mitochondria activity in recipient MSC.

247 , our data suggest that syndecan-3 regulates MSC adhesion and efficacy in inflammatory arthritis, lik

248 , which play key roles in further regulating MSC survival and paracrine signaling.

249 es an insight into the mechanisms regulating MSCs growth and chemo-resistance and suggested a clinica

250 luminate the role of alphaKG in rejuvenating MSCs and ameliorating age-related osteoporosis, with a p

251 tors produced by transcriptionally remodeled MSCs.

252 analysis and functional validation revealed MSC-derived stanniocalcin 1 (STC1) and its transcription

253 Moreover, Sdc3(-/-) MSCs adhered more rapidly to collagen type I and showed

254 ritis, intraarticular injection of Sdc3(-/-) MSCs yielded enhanced efficacy compared to injection of

255 Exposure of bioreactor-seeded MSCs to inflammatory stimuli reproducibly switched MSC s

256 Early stage MSCs showed active inter-state conversions in the excite

257 Later stage MSCs exhibited narrow photoinduced absorptions at lower-

258 ine-like cartilage constructs by stimulating MSC chondrogenic differentiation as cell sheets.

259 have broad implications for use in studying MSC-immune interactions under flow conditions as well as

260 o inflammatory stimuli reproducibly switched MSC secreted factor profiles and altered microvesicle co

261 We conclude that MSC therapy improves survival not through overt hematopo

262 mulatta) of either sex, we demonstrate that MSC-EVs reduce injury-related physiological and morpholo

263 Taken together, our results show that MSC-mediated systemic delivery of oncolytic viruses is a

264 ts and victims of nuclear accidents but that MSCs alone do not significantly accelerate or contribute

265 We conclude that MSCs could be used to ameliorate syndromes triggered by

266 Collectively, these data reveal that MSCs could be an effective countermeasure in cancer pati

267 In vitro coculture experiments showed that MSCs and ECFCs induced self-renewal and genes associated

268 myosin fragmentation or modification in the MSC samples.

269 te the three-dimensional architecture of the MSC in human HEK293T cells.

270 netheless, the structure and function of the MSC remain unclear.

271 o speed up the likelihood computation on the MSC model and the optimal network search.

272 type II collagen expression compared to the MSC monoculture group.

273 All the MSCs could be directly synthesized from conventional mol

274 he effects of the immune response during the MSCs-based virotherapy.

275 scent microscopy was employed to monitor the MSCs and tunneling structure of ECs.

276 tor in designing such constructs is that the MSCs are appropriately primed to differentiate along ost

277 e crosstalk among HSPCs, leukemia, and their MSC niche, and a molecular mechanism whereby AML impairs

278 d physiology, resulting in new approaches to MSC transplantation using extracellular matrix proteins

279 Mitochondrial transfer to MSC is cell-contact dependent and mediated by HSPC conne

280 patients with myeloma by counteracting tumor-MSC interactions.

281 ter values, the cell complexity in wild type MSCs was significantly higher than in Sdc3(-/-) cells an

282 efficacy compared to injection of wild type MSCs.

283 ted osteoblasts, and not to undifferentiated MSCs, and emit NIR fluorescence for functional detection

284 nd surgical intervention was simulated using MSC Marc.

285 results have prompted clinical trials using MSC-based therapy in SOT.

286 titatively predict the consequences of using MSCs for delivering virotherapeutic agents in vivo.

287 creasing the potential of successfully using MSCs in clinical settings.

288 nical impacts of cell sheet technology using MSCs are discussed.

289 nologically detail all clinical trials using MSCs in the field of SOT.

290 al stem cell-derived extracellular vesicles (MSC-EVs), which mediate cell-to-cell inflammatory and tr

291 effects of MSCs are mainly communicated via MSC-secreted cytokines; however, apoptotic and metabolic

292 in mice pretreated with natural EVs, whereas MSCs and CIMVs-MSCs suppressed antibody production in vi

293 cases, substantially - depending on whether MSC methods or traditional phylogenetic methods that app

294 ill currently a controversial debate whether MSCs exert a pro- or anti-tumor action, mathematical mod

295 erentiation of Wharton jelly-derived MSC (WJ-MSC) into iEC.

296 ced the endothelial lineage commitment of WJ-MSC and increased the vasculogenic potential of reprogra

297 This study depicted the reprogramming of WJ-MSC into rEC using unique transcription factor TWIST1 fo

298 Similarly, F360-InP:Zn MSCs could be converted to F408-InP:Zn MSCs, then to F39

299 nP:Zn MSCs could be converted to F408-InP:Zn MSCs, then to F393-InP:Zn MSCs.

300 ted to F408-InP:Zn MSCs, then to F393-InP:Zn MSCs.